Related Experiment Video
Updated: Jun 29, 2026

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
Subglottic mucormycosis in a COVID-19 patient: a rare case report
Behrooz Amirzargar1, Mehrdad Jafari1, Zahra Ahmadinejad2
1Otorhinolaryngology Research Center, Department of Otorhinolaryngology-Head and Neck Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Mucormycosis is an opportunistic fungal infection caused by fungi of Mucorale order. Uncontrolled diabetes mellitus and other immunosuppressive conditions such as neutropenia and corticosteroid therapy are known risk factors. A new risk factor for this infection is COVID-19 which facilitates mucormycosis by different mechanisms. The rhino-orbito-cerebral involvement is the most common form. Involvement of other anatomical regions may occur in rare situations. As we presented here, a 51-year-old woman presented with respiratory distress and subglottic lesion during COVID-19 (Delta variant) treatment which was diagnosed by histopathological examination as a subglottic mucormycosis postoperatively. The patient underwent tracheostomy and debridement of the necrotic tissues followed by antifungal treatment. New manifestations of COVID-19 are appearing over time. The association between coronavirus and mucormycosis of the laryngeal and airway region must be given serious consideration. Current guidelines recommend a combined medical and surgical approach for achieving the best outcome.
Insights
COVID-19 is a new risk factor for mucormycosis, an opportunistic fungal infection. This case highlights a rare subglottic mucormycosis in a patient treated for COVID-19, emphasizing the need for vigilance.
Area of Science:
- Mycology
- Infectious Diseases
- Otolaryngology
Background:
- Mucormycosis is an opportunistic fungal infection caused by Mucorales fungi.
- Known risk factors include uncontrolled diabetes mellitus, neutropenia, and corticosteroid therapy.
- Coronavirus disease 2019 (COVID-19) is an emerging risk factor facilitating mucormycosis through various mechanisms.
Observation:
- A 51-year-old woman developed respiratory distress and a subglottic lesion during treatment for COVID-19 (Delta variant).
- Histopathological examination confirmed subglottic mucormycosis postoperatively.
- The patient required tracheostomy and debridement of necrotic tissue, followed by antifungal treatment.
Findings:
- This case presents a rare instance of subglottic mucormycosis, a less common anatomical site for this infection.
- The association between COVID-19 and mucormycosis in the laryngeal and airway regions is increasingly recognized.
- New clinical manifestations of COVID-19 continue to emerge.
Implications:
- The findings underscore the importance of considering mucormycosis in patients with COVID-19, particularly those with respiratory symptoms.
- A combined medical and surgical approach is recommended for optimal management of mucormycosis.
- Increased awareness and diagnostic vigilance are crucial for addressing this potentially life-threatening fungal infection in the context of COVID-19.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Fungal Group Zygomycota
Atypical Pneumonia
Cytomegalovirus Disease
Cryptococcal Meningitis
Candidiasis

